Evidence map›Paper›PMID 33427909›Full record

Trial reportAnnals of hematology2021

A multicenter phase II study of intrabone single-unit cord blood transplantation without antithymocyte globulin.

Tetsuya Nishida, Takeshi Kobayashi, Masashi Sawa, Shinichi Masuda, Yasuhiko Shibasaki, Tatsunori Goto, Noriko Fukuhara, Nobuharu Fujii, Kazuhiro Ikegame, Junichi Sugita and 16 more

Abstract readClinical Trial, Phase IIMulticenter Study
PubMed Publisher
In one paragraph

Trial report in Annals of hematology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.6field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

26 authors at 12 institutions in 1 country.

Tetsuya NishidaDepartment of Hematology and Oncology, Nagoya University Graduate School of Medicine, 65 Tsurumai, Showa, Nagoya, Aichi, 466-8550, Japan.
Takeshi KobayashiHematology Division, Tokyo Metropolitan Cancer and Infectious diseases Center, Komagome Hospital, Tokyo, Japan.
Masashi SawaDepartment of Hematology and Oncology, Anjo Kosei Hospital, Anjo, Japan.
Shinichi MasudaDivision of Hematology and Oncology, Japanese Red Cross Society Narita Hospital, Narita, Japan.
Yasuhiko ShibasakiDepartment of Hematology, Niigata University Medical and Dental Hospital, Niigata, Japan.
Tatsunori GotoDepartment of Hematology and Oncology, Nagoya University Graduate School of Medicine, 65 Tsurumai, Showa, Nagoya, Aichi, 466-8550, Japan.
Noriko FukuharaDepartment of Hematology, Tohoku University Hospital, Sendai, Japan.
Nobuharu FujiiDepartment of Hematology and Oncology, Okayama University Hospital, Okayama, Japan.
Kazuhiro IkegameDepartment of Hematology, Hyogo College of Medicine Hospital, Nishinomiya, Japan.
Junichi SugitaDepartment of Hematology, Faculty of Medicine, Hokkaido University, Sapporo, Japan.
Takashi IkedaDivision of Hematology and Stem Cell Transplantation, Shizuoka Cancer Center, Shizuoka, Japan.
Yachiyo KuwatsukaDepartment of Advanced Medicine, Nagoya University Hospital, Nagoya, Japan.
Ritsuro SuzukiDepartment of Oncology and Hematology, Shimane University Hospital, Izumo, Japan.
Yuho NajimaHematology Division, Tokyo Metropolitan Cancer and Infectious diseases Center, Komagome Hospital, Tokyo, Japan.
Noriko DokiHematology Division, Tokyo Metropolitan Cancer and Infectious diseases Center, Komagome Hospital, Tokyo, Japan.
Tomonori KatoDepartment of Hematology and Oncology, Anjo Kosei Hospital, Anjo, Japan.
Yuichiro InagakiDepartment of Hematology and Oncology, Anjo Kosei Hospital, Anjo, Japan.
Yoshikazu UtsuDivision of Hematology and Oncology, Japanese Red Cross Society Narita Hospital, Narita, Japan.
Nobuyuki AotsukaDivision of Hematology and Oncology, Japanese Red Cross Society Narita Hospital, Narita, Japan.
Masayoshi MasukoDepartment of Hematology, Niigata University Medical and Dental Hospital, Niigata, Japan.
Seitaro TerakuraDepartment of Hematology and Oncology, Nagoya University Graduate School of Medicine, 65 Tsurumai, Showa, Nagoya, Aichi, 466-8550, Japan.
Yasushi OnishiDepartment of Hematology, Tohoku University Hospital, Sendai, Japan.
Yoshinobu MaedaDepartment of Hematology and Oncology, Okayama University Hospital, Okayama, Japan.
Masaya OkadaDepartment of Hematology, Hyogo College of Medicine Hospital, Nishinomiya, Japan.
Takanori TeshimaDepartment of Hematology, Faculty of Medicine, Hokkaido University, Sapporo, Japan.
Makoto MurataDepartment of Hematology and Oncology, Nagoya University Graduate School of Medicine, 65 Tsurumai, Showa, Nagoya, Aichi, 466-8550, Japan. mmurata@med.nagoya-u.ac.jp.ORCID http://orcid.org/0000-0001-5488-4364
Anjo Kosei Hospital · JPJapanese Red Cross Narita Hospital · JPNagoya University · JPTokyo Metropolitan Komagome Hospital · JPHokkaido University · JPHyogo Medical University · JPNagoya University Hospital · JPNiigata University Medical and Dental Hospital · JPOkayama University Hospital · JPTohoku University Hospital · JPShimane University Hospital · JPShizuoka Cancer Center · JP

Funding

Japan Agency for Medical Research and Development 19ek0510022h0003Japan Society for the Promotion of Science 18K08321
6 · The paper itself

Abstract

To overcome the delayed or failed engraftment after unrelated cord blood transplantation (CBT), we conducted a multicenter phase II study of intrabone single-unit CBT without antithymocyte globulin (ATG) for adult patients with hematological malignancies (UMIN-CTR, UMIN000020997). Sixty-four patients received an intrabone injection of unwashed (n = 61) or washed (n = 3) cord blood after local anesthesia. All injection-related adverse events were mild and resolved spontaneously. Sixty-two patients were evaluable for the efficacy of intrabone CBT of serological HLA-A, -B, and -DR ≥ 4/6 matched cord blood with a median number of 2.57 × 10

Indexed as

AdolescentAdultAgedAntilymphocyte SerumBone and BonesCord Blood Stem Cell TransplantationFemaleFetal BloodGraft vs Host DiseaseHematologic NeoplasmsHumansIncidenceInfusions, IntraosseousJapanMaleMiddle AgedAntilymphocyte SerumAntithymocyte globulinCord blood transplantationEngraftmentGraft-versus-host diseaseIntrabone

Identifiers

PMID33427909
OpenAlexW3120982985

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.